NF1 and neoplasm: As an RTK inhibitor targeting MET and VEGFR2 [85], cabozantinib achieved partial responses in 42% of evaluable patients, producing a median tumor-volume reduction of 15.2% without any progression during treatment, while also demonstrating improvements in pain and quality-of-life measures alongside a manageable toxicity profile in a Phase II single-arm study of children with NF1-associated pNF (NCT02101736).